Please login to the form below

Corlaner

This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter. . Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA ... Corlaner (ivabradine) - the first new medicine for chronic
FDA clears Amgen's Corlaner for heart failure

The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... Corlaner's approval is based on the results of
Amgen banking on three launches in 2015

year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....